Quick Answer
Cellectar Biosciences, Inc. reported Net Income of -$21.79 million for fiscal year 2025.
Cellectar Biosciences, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$21.79M | +51.1% |
| 2024 | -$44.58M | -4.2% |
| 2023 | -$42.77M | -49.5% |
| 2022 | -$28.60M | -18.6% |
| 2021 | -$24.12M | -59.8% |
| 2020 | -$15.09M | -7.1% |
| 2019 | -$14.09M | -6.4% |
| 2018 | -$13.24M | +2.4% |
| 2017 | -$13.56M | -119.4% |
| 2016 | -$6.18M | -12.5% |
| 2015 | -$5.50M | +31.8% |
| 2014 | -$8.05M | +25.3% |
| 2013 | -$10.78M | -22.6% |
| 2012 | -$8.80M | -18.3% |
| 2011 | -$7.44M | -63.0% |
| 2010 | -$4.56M | +26.7% |
| 2009 | -$6.22M | -2.1% |
| 2008 | -$6.09M | -19.7% |
| 2007 | -$5.09M | -428.3% |
| 2006 | -$963.4K | -100.0% |
| 2005 | -$481.8K | -40.6% |
| 2004 | -$342.8K | -15.9% |
| 2003 | -$295.8K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.44M | +69.7% | +18.4% |
| June 30, 2025 | -$5.45M | -492.6% | +17.5% |
| March 31, 2025 | -$6.60M | +75.2% | +55.0% |
| September 30, 2024 | -$14.66M | +16.3% | -1495.1% |
| June 30, 2024 | -$919.4K | +91.0% | +96.5% |
| March 31, 2024 | -$26.64M | -270.5% | -52.1% |
| September 30, 2023 | -$17.52M | -124.3% | -72.1% |
| June 30, 2023 | -$10.18M | -36.9% | -41.6% |
- Cellectar Biosciences, Inc. showed an increase of +51.1% in Net Income compared to the prior fiscal year.
- Over the 2003–2025 period, Cellectar Biosciences, Inc.’s net income has declined by 7267.1% (from -$295.8 thousand to -$21.79 million).
- The most recent figure is from Cellectar Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: